Introduction {#s0005}
============

Chromosomal aneuploidy, defined by gains or losses of chromosomes, is a defining feature of cancers of epithelial origin, i.e., carcinomas [@bb0005], [@bb0010]. Chromosomal aneuploidies occur in a tissue specific distribution: for example, essentially all cervical carcinomas carry extra copies of the long arm of chromosome 3 and the detection of 3q gain in premalignant cervical dysplasia serves as a sensitive and specific biomarker for progression to invasive disease [@bb0015]. Colorectal cancers (CRCs), on the other hand, are defined by copy number gains of chromosomes and chromosome arms 7, 8q, 13 and 20, and losses of 17p and 18q [@bb0020], [@bb0025]. Specific chromosomal aneuploidies occur at early stages of tumorigenesis, i.e., before the transition to invasive disease, and are maintained during disease progression. They persist in distant metastases, and in tumor-derived cell lines [@bb0030], [@bb0035]. We previously showed that, despite a certain degree of intratumor heterogeneity, the tumor population as a whole is defined by these aneuploidies [@bb0040]. Thus, aneuploidies can be considered drivers of carcinogenesis.

Chromosomal aneuploidies in early dysplasias facilitate the acquisition of additional genetic alterations during tumor evolution [@bb0020]. Consequently, several studies utilized yeast, mouse and human cells as model systems to examine their functional impact on the cellular transcriptome and proteome [@bb0045], [@bb0050], [@bb0055], [@bb0060]. These studies revealed that the presence of an extra chromosome is associated with elevated global transcriptional activity. Moreover, Upender and colleagues demonstrated that the insertion of exogenous chromosomes into diploid cells results in increased transcript levels of genes that reside on the trisomic chromosome; this effect is independent of the specific chromosome introduced and of the cell type [@bb0045].

To determine the consequence of aneuploidy on gene expression, we inserted chromosome 13 into the karyotypically stable, mismatch repair deficient CRC line, DLD-1. We analyzed eight independent clones to specifically address the degree of consistency in aneuploidy induced transcriptional deregulation, both locally and throughout the genome. Further elucidation of the mechanistic basis by which such initial genomic alterations confer growth advantages to pre-cancerous cells may open avenues for early targeted therapeutic interventions [@bb0065].

Materials and Methods {#s0010}
=====================

Cell Culture {#s0015}
------------

Somatic cell hybrids were purchased from the Coriell Repository and DLD-1 cells from ATCC (American Type Culture Collection, Manassas, VA) and maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml Penicillin--Streptomycin (all Invitrogen, Grand Island, NY) at 37 °C with 5% CO~2~.. Microcell mediated chromosome transfer (MMCT) was performed as previously described [@bb0045]. Cells that underwent MMCT were selected and maintained in 200ug/ml geneticin (G418, Invitrogen). Chromosome 13 gain was verified using fluorescence in situ hybridization (FISH) on interphase cells. Since DLD-1 cells tend to lose the extra chromosome at higher passages, some clones had fewer than 50% of cells with a gain of chromosome 13. These clones were sub-cloned to obtain a higher percentage (on average 82%) of cells with a chromosome 13 gain ([Supplemental Figure 1](#ec0005){ref-type="supplementary-material"}*A*).

DNA and RNA Extraction {#s0020}
----------------------

DNA, RNA and protein were extracted simultaneously from the same cell passage for each clone. DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen, Venlo, The Netherlands); RNA was extracted using the RNeasy kit (Qiagen). DNA and RNA concentrations were quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA).

Fluorescence *InSitu* Hybridization (FISH) {#s0025}
------------------------------------------

To analyze metaphase chromosomes, cells were treated with 0.02 mg/ml Colcemid (Invitrogen, Grand Island, NY) for 1 hour, suspended in hypotonic solution for 20 minutes, and then fixed using methanol/acetic acid (1:3).

To confirm the presence of an extra copy of chromosome 13, dual color FISH was performed using a contig of three overlapping bacterial artificial chromosome (BAC) clones that contained the *MET* gene on chromosome band 7q31 and two overlapping genes that contained the *CDX2* gene on chromosome band 13q12. The *MET* and *CDX2* contig was labeled by nick-translation with Dy505 (Dyomics, Jena, Germany) and Spectrum Orange-dUTP (Abbott Molecular, Abbott Park, IL), respectively. The FISH procedure is described at <https://ccr.cancer.gov/Genetics-Branch/thomas-ried>.

FISH slides were imaged using a Leica DM-RXA fluorescence microscope (Leica, Wetzlar, Germany) equipped with custom optical filters using a 40x objective.

Array CGH {#s0030}
---------

Array CGH was performed with minor modifications according to the manufacturer (Agilent Technologies, Santa Clara, CA, oligonucleotide array-based CGH for genomic DNA analysis protocol (Version 6.2, October 2010)). DLD-1 clones were labeled in Cyanine 3-dUTP (Perkin Elmer, Waltham, MA) and the corresponding reference DNA (Promega, Madison, WI) was labeled with Cyanine 5-dUTP (Perkin Elmer). Data was extracted using Nexus Copy Number 6.0 Discovery Version (Biodiscovery, Hawthorne, CA).

Gene Expression Microarrays {#s0035}
---------------------------

One color gene expression array was conducted according to Agilent\'s One-Color Microarray-Based Gene Expression Analysis protocol (Version 6.5 May 2010). Extracted RNA was labeled with Cyanine 3-CTP (Perkin Elmer) on an oligonucleotide-based whole human genome microarray. The microarray data was log2 transformed and normalized to 75 percentile according to the protocol by Agilent. PCA analysis was done with Partek Genomics Suite (Partek, St. Louis, MO).

For the current study, Gene Set Enrichment Analysis (GSEA) was used with gene sets extracted from Molecular Signature Database (MSigDB v.4--0) C2 (manually curated gene sets from online pathway databases, publications in PubMed and knowledge of domain experts). Only gene sets with more than 15 genes and less than 500 genes were included in the analysis. Analysis was based on a Fisher\'s exact *t*-test and a weighted scoring scheme with 1000 permutations.

*RASL11A* Plasmid Cloning, Lentivirus Production and Transduction {#s0040}
-----------------------------------------------------------------

The *RASL11A* open reading frame was amplified by PCR from a template plasmid (MHS6278--213243659, Dharmacon, accession \# BC136761.1) and cloned into a pDonr vector using Gateway BP Recombination. Entry clones of the expected size were Sanger sequenced and the validated insert was combinatorially subcloned by LR Gateway Recombination into a puromycin-resistant lentiviral backbone along with Tre3G promoter and IRES-eGFP. Proper recombination was determined by restriction digestion with BsrGI.

The lentiviral expression plasmid was transfected into 293FT cells along with Virapower Packaging Mix. The lentivirus was prepared per the kit manual with Lipofectamine 3000 (ThermoFisher Scientific). Virus was concentrated over Lenti-X Concentrator columns (Takara) and titer analysis was performed by qPCR.

Target cells were seeded in 12-well plates and allowed to attach for 24 hours. Lentiviruses for the RASL11A overexpression vector and the tetracycline-activated transactivator were added to a final MOI (Multiplicity of Infection) of 20 together with 8 μg/ml polybrene. Viruses were removed 24 hours and replaced by fresh medium. Selective medium (blasticidin 5 μg/ml; puromycin 3 μg/ml) was added after 48 hours and cells were selected for 21 days. RASL11A expression was induced using 0.1 ng/ml doxycycline and EGF positive cells were subsequently enriched by FACS sorting.

qRT-PCR {#s0045}
-------

Total RNA was transcribed to complementary DNA using the Verso cDNA synthesis kit (Thermo Fisher Scientific). Quantitative reverse PCR (qRT-PCR) using Power Sybr Green (Applied Biosystems, Foster City, CA) was performed as previously described [@bb0070] using specific primers for *RASL11A* (Forward: AGCTGTATTCACGGCTGGTC Reverse: CATTTGGACAGGGAATCGAC) and the housekeeping gene *YWHAZ* (Forward: ACTTTTGGTACATTGTGGCTTCAA Reverse: CCGCCAGGACAAACCAGTAT) (Eurofins Genomics, Louisville, KY).

Proliferation Assay {#s0050}
-------------------

DLD-1 and DLD-1 + 13 cells were seeded in triplicates in 96 well plates at 2000 cells per well. Cell growth was monitored using CellTiter-Blue Assay (Promega) according to the manufacturer\'s instructions. Briefly, cells were grown for 7 days; 20 μL of CellTiter-Blue was then added to each well and incubated at 37 °C in the dark for 90 minutes. Fluorescence generated by the conversion of the substrate by living cells was measured using a microplate reader SpectraMaxM2^e^ (Molecular Devices, Sunnyvale, CA) at excitation 560 nm and emission 590 nm. Background fluorescence was measured in wells containing media only and subtracted from all other measured fluorescence values. Cell growth was calculated as fold over seeding: \[fluorescence generated from cells at day (x) / fluorescence of cells generated just after seeding (day 0)\]. Three independent experiments were performed, and the Student\'s t-test was used to assess statistical significance (*P* ≤ .05).

Soft Agar Colony Formation Assay {#s0055}
--------------------------------

Soft agar assays were performed in 6well plates as described by Borowitz et al. [@bb0075]. 5000 cells/well plated in the top agar and colonies allowed to grow for 3 weeks. Cells were then labeled with nitroblue tetrazolium overnight, fixed with 4% neutral buffered formaldehyde, and plates scanned using a flatbed scanner. The number of colonies was analyzed using ImageJ 1--49, and statistical analysis performed in GraphPad Prism 7 for Mac.

Scratch Wound Migration Assay {#s0060}
-----------------------------

The scratch wound migration assay was performed using the IncuCyte (Essen BioScience, Ann Arbor, MI), Briefly, 10^5^ cells/well were plated, incubated overnight, and the cell free areas ('scratches') created with the WoundMaker (Essen BioScience). Plates were then placed into the IncuCyte, imaged every 4 h using for 2 days and wound closure as measured by wound density over time analyzed. To compare wound closure for multiple experiments, the area under the graph was calculated. Statistical analysis was performed in GraphPad Prism 7 for Mac.

Western Blot Analysis {#s0065}
---------------------

For Western blot analysis, 40 μg protein was separated on a 4--12% gel using the XCell SureLock Mini-Cell (Thermo Fisher Scientific), transferred to PVDF membranes, and proteins detected using standard procedures. The following antibodies were used: RASL11A; 1:500 (NBP2--30368, Novus Biologicals, Littleton, CO), β-actin; 1:2000 (NP600-S01, Novus Biologicals, Littleton, CO), goat anti-rabbit--HRP (1:3,500, Thermo Fisher Scientific, Waltham, MA).

Results {#s0070}
=======

Generation and Characterization of DLD-1 Cells With Additional Copies of Chromosome 13 {#s0075}
--------------------------------------------------------------------------------------

To establish models to study the consequences of chromosomal aneuploidy and the ensuing genomic imbalances on the cellular transcriptome, we used microcell mediated chromosome transfer (MMCT) to generate gains of chromosome 13 in the diploid and chromosomally stable CRC cell line DLD-1. We confirmed the gain of chromosome 13 in single-cell derived, independent clones by interphase FISH, high-resolution aCGH ([Figure 1](#f0005){ref-type="fig"}, *A* and *B*, [Supplemental Figure 1](#ec0005){ref-type="supplementary-material"}, *A*--*D*), and whole chromosome paints ([Supplemental Figure 1](#ec0005){ref-type="supplementary-material"}*E*). Clones 13--1, 13--2, 13--3 and 13--6 incorporated an intact copy of chromosome 13 ([Figure 1](#f0005){ref-type="fig"}, *A* and *B*). Approximately 50% of the population within clone 13--4 contained four copies of chromosome 13. Furthermore, clone 13--5 was tetraploid with six copies of chromosome 13 ([Figure 1](#f0005){ref-type="fig"}, *A* and *B*). Clone 13--7 had a higher copy gain extending from chromosome bands 13q21.2 to 13q31, while clone 13--8 exhibited a partial gain from the centromere to band 13q21.1 ([Figure 1](#f0005){ref-type="fig"}*B*, [Supplemental Figure 1](#ec0005){ref-type="supplementary-material"}, *B* and *C*). The introduction of chromosome 13 did not induce any other karyotypic changes.Figure 1Characterization of the eight single cell derived clones of DLD-1 + 13 cells. (A) FISH probes corresponding to the *MET* gene (chromosome band 7q31, green signals) and *CDX2* (chromosome band 13q21, red signals) hybridized onto interphase nuclei for the parental DLD-1 WT and the eight DLD-1 + 13 clones. One hundred fifty cells were counted per clone. (B) Genomic aberration profile in the DLD-1 WT clone and all eight DLD-1 + 13 clones using aCGH. (C) Proliferation graph for the DLD-1 WT and four DLD-1 + 13 clones. (D) Percentages of cells (n = 100) with a gain of chromosome 13 as analyzed by FISH for four DLD-1 + 13 clones on day 0 and day 5 without neomycin selection. The FISH probes used were *MET* (7q31) and *CDX2* (13q12). A gain of chromosome 13 was made if there were more copies of *CDX2* as compared to *MET* within the same cell.Figure 1

Gain of Chromosome 13 Reduces Proliferation of DLD-1 Cells {#s0080}
----------------------------------------------------------

Next, we measured the consequences of chromosomal aneuploidy on cell growth. Invariably, the cell lines with an extra copy of chromosome 13 grew slower than the parental DLD-1 line ([Figure 1](#f0005){ref-type="fig"}*C*). Since the cell lines with extra copies of chromosome 13 were cultured in neomycin-containing medium, we asked whether the slower growth of the DLD-1 + 13 clones was attributable to the presence of neomycin. This was not the case ([Supplemental Figure 1](#ec0005){ref-type="supplementary-material"}*F*). Over the course of 5 days, the aneuploid chromosome was maintained without selection, as confirmed by dual color interphase FISH ([Figure 1](#f0005){ref-type="fig"}*D*).

Aneuploidy of Chromosome 13 Alters the Cellular Transcriptome {#s0085}
-------------------------------------------------------------

We next asked how the gain of chromosome 13 affects the cellular transcriptome by analyzing global gene expression levels using microarrays. Principal Component Analysis (PCA) ([Figure 2](#f0010){ref-type="fig"}*A*) showed that aneuploid clones cluster apart from the controls. An exception was clone 13--8, which has a partial chromosome 13 gain and was positioned relatively apart from to the main cluster of derived cell lines. Genome-wide, 464 genes were up-regulated, and 379 were down-regulated (fold change ≥1.5, FDR ≤0.05) in clones 13--1 to 13--8 ([Supplemental Table 1](#ec0015){ref-type="supplementary-material"}, [Supplemental Table 2](#ec0020){ref-type="supplementary-material"}). The reproducibility of the gene expression analyses is presented as correlation plots for chromosomes 13 (the aneuploid chromosome) and 11 (as a control) ([Figure 2](#f0010){ref-type="fig"}, *B* and *C*). The average magnitude of gene expression increase was higher for chromosome 13 (*P* = .0004, FDR = 0.01) compared to other chromosomes. Of the 273 genes on chromosome 13 that were present on the arrays, 20% percent showed significantly elevated expression, while 2.5% were down-regulated in cells with chromosome 13 gain (fold change \>1.5, FDR ≤0.05) ([Figure 2](#f0010){ref-type="fig"}, *D*--*F*). Genes on chromosome 16 were more likely to be down-regulated in clones with gain of chromosome 13 (*P* = .02, FDR ≤0.05) ([Figure 2](#f0010){ref-type="fig"}, *D* and *E*, [Supplemental Table 2](#ec0020){ref-type="supplementary-material"}). We did not observe other predilections for global gene expression changes on a particular chromosome after the addition of chromosome 13 ([Supplemental Table 1](#ec0015){ref-type="supplementary-material"}, [Supplemental Table 2](#ec0020){ref-type="supplementary-material"}). In order to explore pathways that are deregulated as a consequence of adding an additional chromosome 13, we used GSEA, which revealed a significant deregulation of genes associated with the PI3K pathway ([Supplemental Figure 1](#ec0005){ref-type="supplementary-material"}*G*, [Supplemental Table 3](#ec0025){ref-type="supplementary-material"}).Figure 2Transcriptome analysis. (A) Principal component analysis for the five DLD-1 WT biological replicates (red) and the eight DLD-1 + 13 clones (blue). (B) Correlation plots between clone 13--2 and clone 13--3 for genes (log2 ratio) on chromosome 13 (C) Correlation plots between clone 13--2 and clone 13--3 for genes (log2 ratio) on chromosome 11. (D) Chromosome-wide gene expression patterns. The ratio of significant genes on each chromosome after normalization (fold change ≥1.5, FDR ≤0.05) is shown. Each bar represents a chromosome, with chromosome 1 starting from the left. Chromosome 13 is in red and chromosome 16 is in green. (E) Genes from chromosome 11--16 were plotted according to the average log2 ratio for all clones. (F) Heat map for up-regulated (red letters) and down-regulated (blue letters) genes on chromosome 13.Figure 2

Further analysis revealed evidence of region-specific and non-random up-regulation of two discrete clusters of more than three contiguous genes, suggestive of coordinated regulation. The first cluster was located on cytoband 13q13.3 and contained seven highly upregulated genes: *NBEA, MAB21L1, DCLK1, SOHLH2, CCDC169, SPG20* and *CCNA1* (*P* = .0003) ([Figure 3](#f0015){ref-type="fig"}*A*, [Supplemental Table 1](#ec0015){ref-type="supplementary-material"}). The second cluster was located on cytoband 13q32.1 and contained five upregulated genes (*ABCC4, CLDN10, DZIP1, DNAJC3* and *UGGT2*) (*P* = .003), however, the expression was not as high as that of genes found in the first cluster ([Figure 3](#f0015){ref-type="fig"}*A*, [Supplemental Table 1](#ec0015){ref-type="supplementary-material"}). Of note, *RASL11A*, which is located at cytoband 13q12.2, escaped the copy number increased up-regulation and was consistently down-regulated (*P* = .0001, FDR = 0.002) by, on average, 8.6-fold ([Figure 3](#f0015){ref-type="fig"}*A*, [Supplemental Table 2](#ec0020){ref-type="supplementary-material"}).Figure 3(A) All genes on chromosome 13 (log2 ratio) are plotted consecutively for each DLD-1 + 13 clone (x-axis), with each diamond representing one gene. The highest up-regulated group of genes, which belong to the contiguous locus on 13q13.3 are color-coded red. The second up-regulated group of genes on 13q32.1 is color-coded green. *RASL11A*, the most down-regulated gene on chromosome 13, is color-coded blue. The red line depicts the zero line. Genes on chromosome 16 are plotted at the right for comparison. (B) Correlation plot between the *RASL11A* gene expression levels (log2 ratio, x-axis) and the RASL11A protein expression levels (average ratio, y-axis) for all eight DLD-1 + 13 clones.Figure 3

Gain of Chromosome 13 Leads to Decreased Expression of *RASL11A* {#s0090}
----------------------------------------------------------------

We next explored whether gene expression changes resulted in protein level changes of RASL11A using selected reaction monitoring (SRM) mass spectrometry to quantify protein expression levels (Supplemental Materials and Methods). Protein ratios were quantified based on a single unique peptide from duplicate analyses and the coefficient of variation (CV) determined. Indeed, RASL11A protein was down-regulated in all clones. Furthermore, we observed that *RASL11A* mRNA expression correlates with RASL11A protein levels (r^2^ = 0.79, [Figure 3](#f0015){ref-type="fig"}*B*), indicating that *RASL11A* mRNA directly determines RASL11A protein expression levels.

*RASL11A* Expression is Reduced in Colorectal Tumors {#s0095}
----------------------------------------------------

We next aimed to clarify if *RASL11A* expression is decreased in primary CRC in a set of 216 primary rectal cancers and matched normal mucosa [@bb0080]. We found that *RASL11A* mRNA levels were reduced by 1.28 fold in rectal cancers compared to matched normal mucosa (*P* = .0001, FDR = 0.0001) ([Supplemental Table 4](#ec0030){ref-type="supplementary-material"}) [@bb0080]. When comparing 18 CRC derived cell lines that were aneuploid versus those that were diploid (i.e., deficient in mismatch repair), *RASL11A* had a significantly lower expression in aneuploid CRC cell lines (*P* = .0384) ([Figure 4](#f0020){ref-type="fig"}*A*). The aneuploid CRC derived cell lines all had a gain of chromosome 13 except for T84.Figure 4*RASL11A* (A) Box plot of relative *RASL11A* expression levels in 8 aneuploid and 6 diploid CRC cell lines. The x-axis depicts the two groups while the y-axis depicts the relative expression level of *RASL11A*. (B) *RASL11A* relative expression in the transduced DLD-1 WT, clone 13--2 and clone 13--3 normalized to the empty vector (EV) controls. (C) Western blot for RASL11A and the loading control, β-actin for DLD-1 WT with *RASL11A* overexpression and DLD-1 + 13 clone 13--2 with *RASL11A* overexpression. *RASL11A* expression was induced by doxycycline in the indicated concentration. (D) Seven-day growth curve of DLD-1 + 13 clone 13--2 empty vector (EV) and *RASL11A*. (E) Box plot of the number of colonies (y-axis) in DLD-1 + 13 clone 13--3 EV control and *RASL11A* overexpression. \**P* ≤ .05. (F) Scratch assay between DLD-1 WT cells and DLD-1 + 13 clone 13--3 cells. Each compares EV vs *RASL11A* overexpression. \**P* ≤ .05, N.S. = *P* \> .05.Figure 4

*RASL11A* Overexpression Does Not Reduce *InVitro* Tumorigenicity of DLD-1 Cells {#s0100}
--------------------------------------------------------------------------------

In order to test if RASL11A reduces tumorigenicity in vitro, we overexpressed *RASL11A* in DLD-1 + 13 clones (13--2, 13--3, 13--4) and DLD-1 cells ([Figure 4](#f0020){ref-type="fig"}, B and C; [Supplemental Figure 2](#ec0010){ref-type="supplementary-material"}*A*) using a doxycycline-inducible expression system. We additionally expressed *RASL11A* in HT-29 cells, a aneuploid colorectal cancer cell line with a gain of chromosome 13 that showed low expression of *RASL11A* as compared to normal colon mucosa ([Supplemental Figure 2](#ec0010){ref-type="supplementary-material"}*B*) [@bb0085]. Overexpression of *RASL11A* increased cell proliferation compared to control cells (empty vector) in the DLD-1 + 13 clones ([Figure 4](#f0020){ref-type="fig"}*D*). Soft agar assay showed an increased number of colonies in the DLD-1 + 13 *RASL11A* overexpressing cells as compared to the empty vector ([Figure 4](#f0020){ref-type="fig"}*E*), whereas DLD-1 cells showed no differences ([Supplemental Figure 2](#ec0010){ref-type="supplementary-material"}*C*). Using the wound healing assay, we found that DLD-1 + 13 clones overexpressing *RASL11A* tended to close scratches slower than cells expressing the control vector ([Figure 4](#f0020){ref-type="fig"}*F*). In DLD-1 cells, there was no difference when overexpressing *RASL11A*. Interestingly, overexpression of *RASL11A* did not affect colony formation or wound closure in HT29 cells ([Supplemental Figure 2](#ec0010){ref-type="supplementary-material"}, *D* and *E*). Overall, *RASL11A* overexpression increases cell proliferation, and anchorage independent growth while decreasing cell migration in DLD-1 + 13 cells.

In summary, we have established 8 cell lines with additional copies of chromosome 13. This aneuploidy results in a highly reproducible, consistent upregulation of genes on chromosome 13, which, in turn, affects gene expression levels throughout the genome. We conclude that aneuploidy results in a massive deregulation of the transcriptional equilibrium in cancer cells.

Discussion {#s0105}
==========

Aneuploidy is a defining hallmark of carcinomas and results in a tissue specific distribution of genomic imbalances. We now systematically explored how such specific genomic imbalances affect the cellular transcriptome.

In the present study, we inserted chromosome 13 into the diploid colorectal cancer cell line DLD-1, and generated eight independent clones with additional copies of chromosome 13. We detected a consistent and highly reproducible correlation between copy number increase and gene expression levels among the biological replicates. Upender et al. [@bb0045] had determined that the correlation between genomic copy number and gene expression levels is independent of the introduced chromosome, and independent of the recipient cell line. We show that the addition of a chromosome affects a substantial number of genes residing on other chromosomes as well. This global effect was not due to genomic rearrangements as reported by Passerini et al. [@bb0090]. Of note, the transcriptional changes were highly reproducible between replicates. Our DLD-1 + 13 cell lines, not otherwise available, present clean experimental systems to study the consequences of specific aneuploidies on gene expression.

We identified two clusters on chromosome 13 that were specifically subject to gene expression increases as a consequence of the induced aneuploidy, which were not identified in our previous analysis due to the lower density of features on the arrays [@bb0045]. The overexpression of genes on the two specific loci on chromosome 13 is not known to be directly associated with colon cancer and was not found by Camps et al. to be commonly subject to focal amplifications in CRC [@bb0070]. The two identified clusters could potentially be regulating genes on other chromosomes. Nicholson and colleagues found that the overexpression of one gene, *SPG20*, expressed in cluster 13q13.3, promotes cytokinesis failure in the DLD-1 + 13 cells [@bb0095].

Growth impairment was previously observed in cell lines with artificially inserted chromosomes [@bb0050], [@bb0060], [@bb0100]. Consistently, all eight DLD-1 + 13 clones grew significantly slower in comparison to the parental DLD-1 cells, indicating that incorporation of extra genomic material resulted in marked growth impairment. Rutledge et al. observed higher proliferation of the DLD-1 + 13 cells cultured in serum-free conditions or with the addition on 5-FU, which could be due to a selective advantage due to phenotypic differences in the cells [@bb0100].

*RASL11A*, a gene that escaped the genomic copy number induced overexpression, was consistently down-regulated in all DLD-1 + 13 clones. *RASL11A* belongs to a small family of GTPases that are highly similar to RAS proteins and are conserved in eukaryotes [@bb0105]. Functionally, little is known about *RASL11A* other than its role as a chromatin-associated modulator of pre-ribosomal RNA synthesis and its interaction with a putative enhancer characterized by H3K4me1 marks [@bb0110] [@bb0115]. However, it is consistently down-regulated in not only DLD-1 + 13 clones but also in primary rectal cancer samples and CRC derived cell lines. *RASL11A* expression is detectable in the colon, but other than the current study, there is no data regarding *RASL11A* expression in CRC [@bb0105]. *RASL11A* was found consistently down-regulated in prostate cancer, which could suggest a tumor suppressor role [@bb0105]. We found that the overexpression of *RASL11A* in the DLD-1 + 13 clones increases cell proliferation and colony formation in soft agar assays, while at the same time reducing cell migrations. Interestingly, these effects were limited to DLD-1 + 13 cells and were not observed in DLD-1 and HT29 cells. This could be due to genomic content since HT29 has other chromosomal aberrations as well. Orlando and colleagues reduced *RASL11A* levels using short interfering RNA which resulted in decreased cell viability and proliferation [@bb0115]. Our results are consistent with their findings. When we over-expressed RASL11A in HT29 cells, we found only a slight increase in cell proliferation although it was not significant. We conclude that the functions of *RASL11A* are not consistent with the role of a tumor suppressor protein.

In summary, our findings show that the introduction of chromosome 13 into diploid cells has a non-random effect on the expression of genes on chromosomes other than 13, and this effect can result in both down-regulation and up-regulation of gene expression. The effects were consistent among the different clones, suggesting a general, reproducible transcriptional deregulation as a consequence of chromosome-specific aneuploidy.

The following are the supplementary data related to this article.Supplemental Figure 1(A) Percentage of cells (n = 100)(y-axis) with a gain of chromosome 13 using FISH probes corresponding to *MET* and *CDX2* in all eight DLD-1+13 clones (x-axis). (B) Array-CGH depicting the gain of chromosome 13 for clone 13-7. (C) Array-CGH depicting the gain of chromosome 13 for clone 13-8. (D) Array-CGH for clone 13-4 depicting the gain of chromosome 13. The gain of chromosome 2p, 11p and loss of chromosome 6p, are known aberrations in DLD-1 WT cells. (E) Chromosome 13 paint probes (pink) were hybridized on the eight DLD-1 13 clones. (F) Proliferation graph for DLD-1, and Clone 13-2 with and without neomycin. (G) Gene set enrichment analysis for PI3K comparing DLD-1 and DLD-1+13 clones.Supplemental Figure 1Supplemental Figure 2(A) Western blot of DLD-1 WT and clones 13-2 with RASL11A overexpression and the empty vector (EV) control with and without induction of doxycycline (0, 0.1 ng/ml and 1 ng/ml. β-actin served as the loading control. (B) RT-PCR results for HT29, DLD-1 WT and DLD-1+13 clone 13-2 overexpression of *RASL11A* and EV control compared to the uninduced control. (C) Box plot of the number of colonies (y-axis) between DLD-1 WT EV control and DLD-1 WT *RASL11A* overexpression (x-axis). N.S. = *P* \> .05. (D) Scratch assay box plot between HT29 EV and the corresponding *RASL11A* overexpression. N.S. = *P* \> .05. AUC = area under the curve. (E) Box plot of the number of colonies (y-axis) between HT29 EV and *RASL11A* overexpression (x-axis). N.S. = *P* \> .05.Supplemental Figure 2Supplemental Table 1Up-regulated genes on all chromosomesSupplemental Table 1Supplemental Table 2Down-regulated genes on all chromosomesSupplemental Table 2Supplemental Table 3Pathways that are deregulated as a consequence of adding an additional chromosome 13Supplemental Table 3Supplemental Table 4RASL11A mRNA expressionSupplemental Table 4Supplemental Material and MethodsImage 1
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